Pharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial

Pharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial Thetis Pharmaceuticals LLC, a clinical-stage company focused on developing TP-317, a pioneering small molecule drug targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis, has…

Read MorePharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial
Cyrus

Cyrus Selects CYR212 as Candidate for IgG-Driven Autoimmune Diseases

Cyrus Selects CYR212 as Candidate for IgG-Driven Autoimmune Diseases Cyrus Biotechnology, an AI-driven therapeutics company, announced the selection of CYR212 as its clinical development candidate for chronic IgG-driven autoimmune diseases. CYR212 is a next-generation, engineered Immunoglobulin-G (IgG) protease designed to…

Read MoreCyrus Selects CYR212 as Candidate for IgG-Driven Autoimmune Diseases

Peanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers

Peanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers Stallergenes Greer, a biopharmaceutical company specializing in allergen immunotherapy (AIT), has announced that the European Commission (EC) has granted approval for the extension of Palforzia® (defatted powder of Arachis…

Read MorePeanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers

Cardiometabolic Innovator Verdiva Bio Launches with $410M+ Series A to Advance Therapies

Cardiometabolic Innovator Verdiva Bio Launches with $410M+ Series A to Advance Therapies Verdiva Bio Limited (“Verdiva”), a new clinical-stage biopharmaceutical company, announced its official launch today, aiming to innovate therapies for obesity and other cardiometabolic disorders. The company has raised…

Read MoreCardiometabolic Innovator Verdiva Bio Launches with $410M+ Series A to Advance Therapies

Ambry Genetics Data Enhances BRCA2 Variant Classification for Hereditary Cancers

Ambry Genetics Data Enhances BRCA2 Variant Classification for Hereditary Cancers Ambry Genetics, a leader in clinical genomic testing, has announced its contribution to a groundbreaking study published in Nature, which significantly enhances the understanding of BRCA2 gene variants. As genetic…

Read MoreAmbry Genetics Data Enhances BRCA2 Variant Classification for Hereditary Cancers

MaaT Pharma Announces Positive Phase 3 ARES Results for MaaT013 in Acute GvHD

MaaT Pharma Announces Positive Phase 3 ARES Results for MaaT013 in Acute GvHD MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company specializing in Microbiome Ecosystem Therapies™ (MET) to improve survival for cancer patients through immune modulation, has announced positive topline…

Read MoreMaaT Pharma Announces Positive Phase 3 ARES Results for MaaT013 in Acute GvHD

Vir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500

Vir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500 Vir Biotechnology, Inc. (Nasdaq: VIR) has presented encouraging preliminary Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets HER2-expressing solid tumors, and VIR-5500,…

Read MoreVir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500